Skip to content
Screener

BridgeBio Pharma BBIO Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$154.2MBeat by $7.3M
EPS-$1.00Miss by $0.29
Revenue estimate$146.8M
EPS estimate-$0.71

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$267.3M
EPS estimate-$0.67

Financials

Q4 2025

Income statement

See full
Revenue$154.2M+2,521%
Gross profit$146.1M+3,746%
Operating income-$139.6M+38.3%
Net income-$194.6M+27.2%
EPS (diluted)-$0.99+30.3%

Balance sheet

See full
Cash & equivalents$170.5M-75.0%
Total debt$10.0M-97.8%
Total equity-$2.1B-42.1%
Total assets$936.0M+1.8%

Cash flow

See full
Operating cash flow-$56.4M+71.1%
CapEx$33.0K-29.8%
Free cash flow-$56.5M+71.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$14.74B+184%
Enterprise value$14.58B+195%
P/S29.4×+6.0×

Profitability

See full
Gross margin95.8%-2.4pp
Operating margin-104.2%-39.5pp
Net margin-146%-42.0pp
FCF margin-89%—

Returns & leverage

See full
Current ratio2.8×-1.9×

Segments

By product

See full
Cost of license, services, and royalty revenue$4.4M—
License and services revenue$2.9M—

By segment

See full
Reportable Segment$154.2M—

FAQ

When did BridgeBio Pharma report Q4 2025 earnings?
BridgeBio Pharma (BBIO) reported Q4 2025 earnings on February 24, 2026 after market close.
What were BridgeBio Pharma's Q4 2025 revenue and EPS?
BridgeBio Pharma reported revenue of $154.2M and eps of $-1.00 for Q4 2025.
Did BridgeBio Pharma beat estimates in Q4 2025?
Revenue beat the consensus estimate of $146.8M by $7.3M. EPS missed the consensus estimate of $-0.71 by $0.29.
How did BridgeBio Pharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2521.2% from $5.9M a year earlier and eps grew 23.7% from $-1.31.
Where can I find BridgeBio Pharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001743881-26-000008) and the 10-K periodic report (0001743881-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.